# Teva Sets 2030 Innovative Medicines Revenue Target at $6 Billion to $7 Billion

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/54920
Published: 2026-11-12T04:36:36.000Z
Updated: 2026-11-12T04:36:36.000Z
Section: Business

> Teva presented the target at its Nov. 11 R&D Day.

Teva set a target of $6 billion to $7 billion in revenue from innovative medicines by 2030 at its Nov. 11 R&D Day, putting a figure on one of its long-term financial goals. The figure is a target, not a reported revenue result.